Relgaabi Capsule
Product Images NDC 58657-234

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Relgaabi (NDC 58657-234). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Method Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

Line graph showing mean pain scores over 8 weeks for placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks (Baseline to 8 weeks), and the y-axis represents mean pain scores (1 to 10). The graph marks a 4-week dose titration followed by a 4-week fixed dose period, with Gabapentin showing a decrease in mean pain score over time compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing mean pain scores over 7 weeks comparing placebo and gabapentin at 1800 mg/day and 2400 mg/day dosages. The x-axis represents weeks including a 3-week dose titration period and 4-week fixed dose period, while the y-axis shows mean pain scores. Gabapentin groups show decreasing pain scores over time compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares placebo (PBO) versus Gabapentin (GBP) at different dosages in two studies, showing percentages of responders. Study 1 bars represent 12% for PBO and 29% for GBP 3600 mg, with statistical significance indicated. Study 2 bars represent 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, with statistical significance noted.*

FDA Label Image

Image-04 (Image 04)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine levels, and a gender adjustment factor (0.85 for female patients).*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to a carbon atom with amino and carboxyl functional groups. The illustration depicts the molecular arrangement relevant to the active ingredient in RELGAABI capsules.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing the percentage difference on the vertical axis and daily dose in mg on the horizontal axis. Three studies labeled as Study a, Study b, and Study c are plotted with distinct symbols. Data points range from 600 mg to 1800 mg daily dose with corresponding percentage differences approximately between 7% and 18%.*

FDA Label Image

Label (Label 231 01)

RELGAABI 200 mg capsules label featuring gabapentin as the active ingredient. The label indicates a package size of 100 capsules, prescription use only, and is produced by Method Pharmaceuticals, LLC. It includes storage instructions and a barcode on the side, with the product name and dosage prominently displayed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.